Chen Chen, Zhou Yifan, Wang Jingqi, Yan Yaping, Peng Lisheng, Qiu Wei
Department of Neurology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Key Laboratory of the Ministry of Education for Medicinal Resources and Natural Pharmaceutical Chemistry, National Engineering Laboratory for Resource Development of Endangered Crude Drugs in Northwest of China, College of Life Sciences, Shaanxi Normal University, Xi'an, China.
Front Immunol. 2018 Jun 4;9:1256. doi: 10.3389/fimmu.2018.01256. eCollection 2018.
Multiple sclerosis (MS) is an immune-mediated demyelinating disease of the central nervous system. Growing evidence has proven that T helper 17 (Th17) cells are one of the regulators of neuroinflammation mechanisms in MS disease. Researchers have demonstrated that some microRNAs (miRNAs) are associated with disease activity and duration, even with different MS patterns. miRNAs regulate CD4 T cells to differentiate toward various T cell subtypes including Th17 cells. In this review, we discuss the possible mechanisms of miRNAs in MS pathophysiology by regulating CD4 T cell differentiation into Th17 cells, and potential miRNA targets for current disease-modifying treatments.
多发性硬化症(MS)是一种中枢神经系统的免疫介导性脱髓鞘疾病。越来越多的证据表明,辅助性T细胞17(Th17)是MS疾病神经炎症机制的调节因子之一。研究人员已经证明,一些微小RNA(miRNA)与疾病活动度和病程相关,甚至与不同的MS模式相关。miRNA调节CD4 T细胞向包括Th17细胞在内的各种T细胞亚型分化。在本综述中,我们讨论了miRNA通过调节CD4 T细胞分化为Th17细胞在MS病理生理学中的可能机制,以及当前疾病修饰治疗的潜在miRNA靶点。